CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large decrease in short interest in April. As of April 30th, there was short interest totaling 167,953 shares, a decrease of 54.9% from the April 15th total of 372,157 shares. Based on an average daily trading volume, of 151,788 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.8% of the shares of the stock are sold short.

Institutional Investors Weigh In On CalciMedica

A number of hedge funds have recently added to or reduced their stakes in CALC. 180 Wealth Advisors LLC grew its holdings in CalciMedica by 297.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after acquiring an additional 94,650 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in CalciMedica during the 4th quarter worth about $506,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in CalciMedica during the 3rd quarter worth about $165,000. PVG Asset Management Corp bought a new position in shares of CalciMedica in the 4th quarter valued at about $302,000. Finally, Renaissance Technologies LLC boosted its stake in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after purchasing an additional 39,775 shares during the last quarter.

CalciMedica Stock Up 0.3%

NASDAQ:CALC traded up $0.00 during mid-day trading on Friday, reaching $0.68. 215,416 shares of the company were exchanged, compared to its average volume of 881,419. CalciMedica has a 12 month low of $0.46 and a 12 month high of $7.20. The company has a fifty day moving average of $0.64 and a 200 day moving average of $2.52. The stock has a market cap of $10.78 million, a PE ratio of -0.52 and a beta of 0.85.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.69) EPS for the quarter. On average, equities research analysts anticipate that CalciMedica will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CALC has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, January 29th. Oppenheimer dropped their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.